China Resources Pharmaceutical Group Ltd. (HK:3320)
:3320
Want to see HK:3320 full AI Analyst Report?
3320 Stock Chart & Stats
HK$4.61
HK$0.05(0.94%)
At close: 4:00 PM EST
HK$4.61
HK$0.05(0.94%)
Day’s Range― - ―
52-Week RangeHK$4.34 - HK$6.53
Previous CloseN/A
Volume6.08M
Average Volume (3M)13.76M
Market Cap
HK$29.59B
Enterprise ValueHK$103.60B
Total Cash (Recent Filing)HK$58.73B
Total Debt (Recent Filing)HK$104.87B
Price to Earnings (P/E)6.7
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.95%
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.74Price Target Upside46.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Business ModelVertical integration across distribution, retail and manufacturing gives durable competitive advantages: control of supply chain, cross‑sell between channels and scale in logistics. That structural setup supports stable revenues and resilience to single-channel disruptions over months.
Steady Revenue Growth & Margin ImprovementConsistent mid-single-digit revenue growth with recent gross margin improvement reflects persistent demand and modest operating progress. Over 2–6 months this trend supports predictable top-line cash generation and provides room to improve operating leverage if cost control persists.
Strong Free Cash Flow GenerationHigh and consistent free cash flow relative to reported earnings signals earnings quality and internal funding capacity. Durable FCF allows reinvestment, working-capital support for distribution and retail, and underpins dividend or debt service capabilities absent major capital shocks.
Bears Say
Rising Financial LeverageMaterial increase in leverage to a debt-to-equity near 1.8 raises structural financial risk. Higher debt magnifies interest and refinancing sensitivity, constrains strategic flexibility, and reduces buffer against sector shocks, making the company more exposed if credit costs rise.
Very Thin Net MarginsPersistently low net margins indicate limited pricing power or a high cost base; small adverse cost or volume swings can materially hit profits. Over months this constrains capacity to build equity, fund growth internally, and absorb higher financing costs tied to the rising leverage.
Cash Flow Vs. Debt Coverage WeakAlthough FCF is strong relative to earnings, operating cash flow covers a very small share of total debt, slowing possible deleveraging. Structurally this raises refinancing and liquidity risk if market credit tightens or interest rates climb, impairing long-term financial flexibility.
China Resources Pharmaceutical Group Ltd. News
3320 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was HK$4.34 and its highest was HK$6.53 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is HK$29.59B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Currently, no data Available
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Undervalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. pays a Quarterly dividend of HK$0.079 which represents an annual dividend yield of 2.95%. See more information on China Resources Pharmaceutical Group Ltd. dividends here
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:3320
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$6.74 (46.20% Upside)
HK$6.74 (46.20% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
7.98%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
3320 Stock 12 Month Forecast
Average Price Target
HK$6.74
▲(46.20% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---